Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalMental HealthDepressionTrial Update

Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

Published: June 11, 2026
Updated: June 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Mental Health / Depression
Company: MUSC Primary Care clinics
Asset: Moodivate
Trial SummaryCLN

Phase III

Mental Health / Depression

Status

Initiated

Sponsor

MUSC Primary Care clinics

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

Why it matters

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

What changed

Trial Update

Analysis

A pilot trial is evaluating a digitally enhanced stepped-care approach for treating depression in primary care settings.

The pilot trial of a digitally enhanced stepped-care approach for depression could redefine treatment paradigms in primary care, particularly in the mental health space. Its success may lead to significant shifts in how depression is managed, impacting both traditional therapy models and digital health competitors.

Monitor results on feasibility and PHQ-9 score changes, as well as potential scalability of the approach in broader settings.

Related companies & assets

Companies

  • View signals for MUSC Primary Care clinics →
  • View signals for telebehavioral health providers →
  • View signals for digital mental health solutions →

Assets

  • Moodivate →

Sources & Humanexa intelligence

Source links

  • Digitally Enhanced Stepped-Care for Depression in Primary Care ↗
  • Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated ↗

Related Humanexa pages

  • Pilot Trial of Digitally Enhanced Stepped-Care for Depression in Primary Care Initiated →

Related signals

Trial SummaryCLN

Phase III

Oncology / Breast Cancer

Status

Active

Sponsor

Roche

Signal Score

8.2

Clinicalhigh signal

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

June 18, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / BRAF/MEK Inhibitors

Status

Initiated

Sponsor

Novartis

Signal Score

8.2

Clinicalhigh signal

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

June 18, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.